AptarGroup Achieves Record Quarterly Results; Plans to Increase Capacity for Aptar Stelmi and Also E

Before you go, we thought you'd like these...
Before you go close icon

AptarGroup Achieves Record Quarterly Results; Plans to Increase Capacity for Aptar Stelmi and Also Expand Aptar's Latin American Presence

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- AptarGroup, Inc. (NYS: ATR) today reported record quarterly sales and achieved record earnings per share when charges related to its European Operations Optimization plan are excluded. AptarGroup also announced it is increasing capacity at its Aptar Stelmi facilities in Europe, and establishing a new Aptar manufacturing facility in Colombia to serve the Andean region.

Second Quarter 2013 Summary

  • Reported sales increased 11% from the prior year to a record $641 million (core sales excluding currency effects and the Aptar Stelmi acquisition increased 4%)
  • Reported earnings per share increased to $0.73 from $0.61 in the prior year
  • Earnings per share excluding charges related to the European Operations Optimization (EOO) plan reached an all-time quarterly high of $0.77, up $0.11 or 17% compared to $0.66 in the prior year when costs associated with the Stelmi acquisition are excluded from prior year results
  • Aptar Stelmi contributed $0.07 to earnings per share
  • Pharma and Food + Beverage segments reported strong sales and profit growth
  • Continued softness in the U.S. hampered Beauty + Home results
  • Aptar Stelmi capacity to be increased
  • Plans were announced for a new Aptar facility to serve the Andean region

SECOND QUARTER RESULTS

For the quarter ended June 30, 2013, reported sales increased 11% to $641 million from $578 million a year ago. Aptar Stelmi, which was acquired in July of 2012, contributed approximately $39 million or 7% to the quarterly sales growth. Changes in currency exchange rates did not impact consolidated sales compared to the prior year.

Second Quarter Segment Sales Analysis

(Change Over Prior Year)

 
   

Beauty +
Home

   Pharma   

Food +
Beverage

   

Total
AptarGroup

Product Sales (including tooling)2%   8%   10%   4%
Currency Effects1%1%
Acquisitions    29%       7%
Total Reported Growth2%   38%   11%   11%
 

Commenting on the quarter, Stephen Hagge, President and CEO, said, "We are pleased to report record quarterly sales. End market diversity continues to be a key strength of our business. Our Pharma segment benefited from increased demand from both the consumer health care and prescription drug markets while our Food + Beverage segment also experienced increased sales to each of its markets. In our Beauty + Home segment, increased demand from the personal care market was partially offset by decreased demand from the beauty and home care markets. Also, Aptar Stelmi continued to perform well."

Hagge continued, "Earnings, before any effects of our European Operations Optimization plan, reached a record level due to the strong performances of our legacy Pharma business, Aptar Stelmi, and our Food + Beverage business. While showing improvement from the first quarter of 2013, our Beauty + Home segment's second quarter results compared to the prior year were negatively impacted by decreased sales to the beauty and home care markets."

In the quarter, AptarGroup recognized charges related to its EOO plan and this had a negative effect on earnings per share of approximately $0.04. AptarGroup's previous earnings per share guidance for the second quarter did not include any impact from this optimization plan. Second quarter earnings per share, excluding the charges related to this plan, were $0.77 and this compared to $0.66 per share for the same period a year ago when costs associated with the Stelmi acquisition (approximately $0.05 per share) are excluded from the prior year results.

YEAR-TO-DATE RESULTS

For the six months ended June 30, 2013, reported sales increased 8% to $1.26 billion from $1.17 billion a year ago. Aptar Stelmi contributed approximately $74 million or 6% to the year-to-date sales growth. Changes in currency exchange rates did not impact consolidated sales compared to the prior year.

Six Months Year-to-Date Segment Sales Analysis

(Change Over Prior Year)

 
   

Beauty +
Home

   Pharma   

Food +
Beverage

   

Total
AptarGroup

Product Sales (including tooling)-1%   2%   11%   2%
Currency Effects1%
Acquisitions    27%       6%
Total Reported Growth-1%   29%   12%   8%
 

Hagge commented on the year-to-date results, "Our core sales growth for the first half of the year reflected the consistently strong performance of our Food + Beverage segment and the rebound in the second quarter of our Pharma segment. Our Beauty + Home segment sales were negatively affected by the softness in the U.S. relative to other regions. Aptar Stelmi had an outstanding first half."

Hagge continued, "Our earnings, excluding any effects of our European Operations Optimization plan, improved due to the contribution from the Aptar Stelmi acquisition and the strength of our Pharma and Food + Beverage segments."

AptarGroup reported earnings per share of $1.31 compared to $1.24 a year ago. Charges related to the Company's EOO plan had a negative effect on earnings per share in 2013 of approximately $0.09, and prior year earnings per share included the negative effect of approximately $0.06 related to costs associated with the Stelmi acquisition. Year-to-date 2013 earnings per share, excluding the charges related to the EOO plan, were $1.40 and this compared to $1.30 per share for the same period a year ago when costs associated with the Stelmi acquisition are excluded from the prior year results.

GEOGRAPHIC EXPANSION PLANS

AptarGroup announced plans to increase the capacity of its Aptar Stelmi business with a $26 million investment for expanded facilities, new equipment and upgraded technology over the next year. Aptar Stelmi, which was acquired by AptarGroup in July of 2012, is a European-based supplier of elastomer primary packaging components to the injectable drug delivery industry. Aptar Stelmi's products include syringe plungers, vial stoppers, and needle shields. Hagge stated, "Aptar Stelmi is benefiting from the growth in the injectable drug delivery industry and the current production facilities are nearly at full capacity. While our long-term objective is to establish a production facility closer to growing markets outside of Europe, our initial investment in capacity expansion will be at Aptar Stelmi's existing facilities in Europe. This will allow us to better serve our existing customers and integrate the new technology before we expand globally."

After decades of serving customers in the Andean region by importing products from various facilities, AptarGroup is establishing a production facility in Colombia which is intended to be operational by mid-2014. In addition to regional customers, several of Aptar's multinational customers have operations in the region. "We have been selling into the Andean region for some time and we want to better serve our customers with a local facility," said Hagge. "Our initial capital investment in this operation is expected to be approximately $5 million over the next 18 months. We are optimistic about the growth potential for each of our segments in this region."

EUROPEAN OPERATIONS OPTIMIZATION PLAN UPDATE

Commenting on the previously announced operations optimization plan, Hagge stated, "Our plan is on schedule and progressing well."

In the second quarter, AptarGroup recognized approximately $3.1 million of expense related to the plan, of which $0.6 million were non-cash expenses. For the year-to-date, AptarGroup recognized approximately $7.6 million of expense related to the plan, of which $1 million were non-cash expenses. Using current exchange rates, AptarGroup expects to recognize approximately $6 million in additional costs, most of which will be incurred in 2013. Savings from the plan are expected to be approximately $12 million on an annualized basis.

OUTLOOK

Commenting on AptarGroup's outlook, Hagge said, "Looking to the third quarter, we anticipate that each of our business segments will grow over the prior year. Even though we expect challenges in several of the markets we serve, the diversity of our product portfolio, geographic presence, customer base and end markets, protect us from exposure to softness in any particular market or region."

AptarGroup expects earnings per share for the third quarter, before costs associated with the EOO plan, to be in the range of $0.68 to $0.73 per share compared to $0.62 per share reported in the prior year. Prior year results include a negative impact of $0.02 per share from Aptar Stelmi's results which included acquisition accounting adjustments.

SHARE REPURCHASE PROGRAM AND CASH DIVIDEND

As previously announced, the Board of Directors increased the number of shares authorized for repurchase by 4 million shares bringing the total currently authorized for repurchase to 5.2 million shares. The Board also declared on July 18, 2013, a quarterly dividend of $0.25 per share, payable August 21, 2013 to shareholders of record as of July 31, 2013.

OPEN CONFERENCE CALL

There will be a conference call on Thursday, July 25, 2013 at 8:00 a.m. Central Time to discuss AptarGroup's second quarter results for 2013. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investor Relations page at www.aptar.com. Replay of the conference call can also be accessed on the Investor Relations page of the website.

AptarGroup, Inc. is a leading global supplier of a broad range of innovative dispensing systems for the beauty, personal care, home care, pharmaceutical, food, and beverage markets. AptarGroup is headquartered in Crystal Lake, Illinois, with manufacturing facilities in North America, Europe, Asia and South America. For more information, visit www.aptar.com.

This press release contains forward-looking statements.Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's beliefs as well as assumptions made by and information currently available to management.Accordingly, AptarGroup's actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist including, but not limited to, economic, environmental or political conditions in the various markets and countries in which AptarGroup operates, changes in customer and/or consumer spending levels including the recent slowdown in Europe; financial conditions of customers and suppliers; fluctuations in the cost of raw materials, components and other input costs; the Company's ability to increase prices, contain costs and improve productivity; the timing and successful completion of our European operations optimization plan; changes in capital availability or cost, including interest rate fluctuations; the competitive marketplace; fiscal and monetary policy; changes in foreign currency exchange rates; direct or indirect consequences of acts of war or terrorism; and labor relations.For additional information on these and other risks and uncertainties, please see AptarGroup's filings with the Securities and Exchange Commission, including its Form 10-K's and Form 10-Q's. Readers are cautioned not to place undue reliance on forward-looking statements.AptarGroup undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

 
 
 
APTARGROUP, INC.
Condensed Consolidated Financial Statements (Unaudited)
    
(In Thousands, Except Per Share Data)
CONSOLIDATED STATEMENTS OF INCOME
 
Three Months EndedSix Months Ended
June 30, June 30,

2013

2012

2013

2012

 
Net Sales$641,441$577,503$1,259,074$1,170,001

Cost of Sales (exclusive of depreciation shown below)

431,351390,225849,837791,295

Selling, Research & Development and Administrative

88,11187,840182,418176,339
Depreciation and Other Amortization (1)38,61432,59774,78565,151
Restructuring Initiatives 2,511  (215) 6,578  (215)
Operating Income80,85467,056145,456137,431
Other Income/(Expense):
Interest Expense(5,442)(3,904)(10,523)(9,146)
Interest Income8467941,6951,822
Equity in results of affiliates(61)(158)(323)(289)
Miscellaneous, net 73  (1,247) (633) (1,000)
Income before Income Taxes76,27062,541135,672128,818
Provision for Income Taxes 26,390  20,889  45,814  43,353 
Net Income$49,880$41,652$89,858$85,465
 
Net (Gain)/Loss Attributable to Noncontrolling Interests (78) 34  (27) 30 
Net Income Attributable to AptarGroup, Inc.$49,802 $41,686 $89,831 $85,495 
Net Income Attributable to AptarGroup, Inc. Per Common Share:
Basic$0.75 $0.63 $1.36 $1.29 
Diluted$0.73 $0.61 $1.31 $1.24 
 
Average Numbers of Shares Outstanding:
Basic66,42066,58066,28866,388
Diluted68,10668,75868,33968,940
 
(1) Depreciation and Amortization for the quarter and year-to-date ended June 30, 2013 included approximately $0.6 million and $1 million, respectively, of accelerated depreciation related to the European Operations Optimization plan.
 
 
 

APTARGROUP, INC.
Condensed Consolidated Financial Statements (Unaudited)
(continued)
(In Thousands)
CONSOLIDATED BALANCE SHEETS
  
June 30, 2013December 31, 2012
ASSETS
 
Cash and Equivalents$189,990$229,755
Receivables, net455,935396,788
Inventories337,625321,885
Other Current Assets 101,070 90,505
Total Current Assets1,084,6201,038,933
Net Property, Plant and Equipment836,708848,233
Goodwill, net346,730351,552
Other Assets 71,323 85,694
Total Assets$2,339,381$2,324,412
 
LIABILITIES AND EQUITY
 
Short-Term Obligations$35,277$74,654
Accounts Payable and Accrued Liabilities 404,001 380,669
Total Current Liabilities439,278455,323
Long-Term Obligations352,636352,860
Deferred Liabilities 136,805 135,731
Total Liabilities928,719943,914
 
AptarGroup, Inc. Stockholders' Equity1,410,0221,379,890
Noncontrolling Interests in Subsidiaries 640 608
Total Equity 1,410,662 1,380,498
 
Total Liabilities and Equity$2,339,381$2,324,412
 
 
 

APTARGROUP, INC.
Condensed Consolidated Financial Statements (Unaudited)
(continued)
(In Thousands)
SEGMENT INFORMATION
      
Three Months EndedSix Months Ended
June 30,   June 30,
 

2013

2012

2013

2012

NET SALES

Beauty + Home$374,984$369,284$738,456$746,435
Pharma182,931132,979351,800273,022
Food + Beverage 83,526  Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners

Gift Finder Promo
More to Explore
Sat, Dec 03
Set Your Location
City, State, or Zip